Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia

M. W. DeGregorio, C. J. Carrera, J. C. Klock, C. H. Pegelow, J. R. Wilbur

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

Original languageEnglish (US)
Pages (from-to)2085-2088
Number of pages4
JournalCancer Treatment Reports
Volume66
Issue number12
StatePublished - 1982
Externally publishedYes

Fingerprint

Daunorubicin
Leukemia
Plasma Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Pharmaceutical Preparations
Regimen B
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

DeGregorio, M. W., Carrera, C. J., Klock, J. C., Pegelow, C. H., & Wilbur, J. R. (1982). Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia. Cancer Treatment Reports, 66(12), 2085-2088.

Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia. / DeGregorio, M. W.; Carrera, C. J.; Klock, J. C.; Pegelow, C. H.; Wilbur, J. R.

In: Cancer Treatment Reports, Vol. 66, No. 12, 1982, p. 2085-2088.

Research output: Contribution to journalArticle

DeGregorio, MW, Carrera, CJ, Klock, JC, Pegelow, CH & Wilbur, JR 1982, 'Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia', Cancer Treatment Reports, vol. 66, no. 12, pp. 2085-2088.
DeGregorio, M. W. ; Carrera, C. J. ; Klock, J. C. ; Pegelow, C. H. ; Wilbur, J. R. / Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia. In: Cancer Treatment Reports. 1982 ; Vol. 66, No. 12. pp. 2085-2088.
@article{d20e9e036ae84a38b3c01ab1c783a0a2,
title = "Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia",
abstract = "Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.",
author = "DeGregorio, {M. W.} and Carrera, {C. J.} and Klock, {J. C.} and Pegelow, {C. H.} and Wilbur, {J. R.}",
year = "1982",
language = "English (US)",
volume = "66",
pages = "2085--2088",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Cellular and plasma kinetics of daunorubicin by two methods of administration in a patient with acute leukemia

AU - DeGregorio, M. W.

AU - Carrera, C. J.

AU - Klock, J. C.

AU - Pegelow, C. H.

AU - Wilbur, J. R.

PY - 1982

Y1 - 1982

N2 - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

AB - Leukemic cell and plasma concentrations of daunorubicin were examined serially in a patient with acute lymphoblastic leukemia following administration of the drug by two different regimens: A an iv bolus dose of 50 mg/m 2, and regimen B a loading dose of 15 mg/m 2 followed by 35 mg/m 2 infused over 4 hours. Peak plasma levels were four times higher after regimen A than B, whereas leukemic cell concentrations were not significantly different. No difference in acute toxicity or therapeutic efficacy was seen after either method of administration. However, we have demonstrated that peak plasma levels of daunorubicin can be reduced by continuous infusion without significantly altering target tissue concentrations.

UR - http://www.scopus.com/inward/record.url?scp=0020366688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020366688&partnerID=8YFLogxK

M3 - Article

C2 - 6958366

AN - SCOPUS:0020366688

VL - 66

SP - 2085

EP - 2088

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -